Concord Biotech to list on Friday. Here’s what GMP suggests
Analysts are of the opinion that a market premium of over 15% on the issue price is justified based on the company's business model, which comprises many niche biopharma products
Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.
